# US 2013/0253013 A1 · Serotonin reuptake inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0253013 A1
- Document ID: US20130253013A1
- Status: Published application
- Kind: A1
- Application number: 13/899,841
- Filed: 2013-05-22
- Published: 2013-09-26
- Earliest claimed: 2010-10-11
- Assignees: Theravance, Inc.
- Applicants: Theravance, Inc.
- Inventors: Eric L. Stangeland; Lori Jean Patterson; Daisuke Roland Saito
- Web page: https://patentgrep.com/patent/US20130253013A1

## CPC

- C07D 207/08: with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 3/14: for calcium homeostasis (vitamin D A61P3/02; parathyroid hormones A61P5/18; calcitonin A61P5/22; osteoporosis A61P19/10; bone metastasis A61P35/04)
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/10: for osteoporosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 207/12: Oxygen or sulfur atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

In one aspect, the invention relates to compounds of formula I: where X, Y, R1, R2, R3, R4, R4, and n are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

## Claims

### Claim 1

(canceled)

### Claim 2 (depends on 22)

The method of claim 22, where R1 is selected from methyl, ethyl, isopropyl, —(CH2)2NHC(O)CH3, —(CH2)2OH, —(CH2)C(O)OCH3, phenyl, 4-phenylacetamide, and 4-pyridyl.

### Claim 3 (depends on 2)

The method of claim 2, where R1 is methyl.

### Claim 4 (depends on 22)

The method of claim 22, where R2 is hydrogen.

### Claim 5 (depends on 22)

The method of claim 22, where R3 is selected from hydrogen and cyano.

### Claim 6 (depends on 5)

The method of claim 5, where R3 is hydrogen.

### Claim 7 (depends on 22)

The method of claim 22, where R4 is selected from halo, —C1-6alkyl optionally substituted with 1 to 5 fluoro atoms, —O—C1-6alkyl optionally substituted with 1 to 5 fluoro atoms, and —NO2.

### Claim 8 (depends on 7)

The method of claim 7, where R4 is —CF3.

### Claim 9 (depends on 22)

The method of claim 22, where n is 1.

### Claim 10 (depends on 22)

The method of claim 22, where X and Y are —CH—.

### Claim 11 (depends on 10)

The method of claim 10, where R1 is selected from —C1-6alkyl optionally substituted with —NHC(O)CH3; —C1-2alkylene-OR; —C1-2alkylene-COOR; phenyl optionally substituted with —NHC(O)CH3; and -pyridyl; where R is selected from hydrogen and —C1-3alkyl; R2 is selected from hydrogen, —C1-6alkyl, and —O—C1-6alkyl; R3 is selected from hydrogen and cyano; and R4 is selected from halo; —C1-6alkyl optionally substituted with 1 to 5 fluoro atoms; —O—C1-6alkyl optionally substituted with 1 to 5 fluoro atoms; and —NO2.

### Claim 12 (depends on 22)

The method of claim 22, where X is —CH— and Y is —N—.

### Claim 13 (depends on 12)

The method of claim 12, where R1 is —C1-6alkyl; R2 is hydrogen; R3 is hydrogen; R4 is selected from halo and —C1-6alkyl optionally substituted with 1 to 5 fluoro atoms; and n is 1.

### Claim 14 (depends on 22)

The method of claim 22, where X is —N— and Y is —CH—.

### Claim 15 (depends on 14)

The method of claim 14, where R1 is —C1-6alkyl; R2 is hydrogen; R3 is hydrogen; R4 is selected from halo and —C1-6alkyl optionally substituted with 1 to 5 fluoro atoms; and n is 1.

### Claim 16 (depends on 22)

The method of claim 22, wherein the compound of formula I has a configuration selected from:
or is enriched in a stereoisomeric form having said configuration.

### Claim 17 (depends on 22)

The method of claim 22, wherein the compound of formula I has a configuration selected from:
or is enriched in a stereoisomeric form having said configuration.

### Claim at position 18

18-21. (canceled)

### Claim 22

A method of treating pulmonary arterial hypertension, comprising administering to a patient a therapeutically effective amount of a compound of formula I:
where:
X and Y are —CH—, or X is —CH— and Y is —N—, or X is —N— and Y is —CH—;
R1 is selected from —C1-6alkyl optionally substituted with 1 to 5 groups selected from halo, —NHC(O)CH3, and —C(O)NHCH3; —C3-6cycloalkyl; —C1-2alkylene-OR; —C1-2alkylene-COOR; —C0-3alkylene-phenyl optionally substituted with —NHC(O)CH3 or —C(O)NHCH3; and —C0-3alkylene-pyridyl; where R is selected from hydrogen and —C1-3alkyl;
R2 is selected from hydrogen, —C1-6alkyl, and —O—C1-6alkyl;
R3 is selected from hydrogen, halo, and cyano;
R4 is selected from halo; —C1-6alkyl optionally substituted with 1 to 5 fluoro atoms; —O—C1-6alkyl optionally substituted with 1 to 5 fluoro atoms; —C0-1alkylene-phenyl; —O—C0-3alkylene-phenyl; —SO2—C1-6alkyl; —C(O)NH2; and —NO2; and
n is 1 or 2;
or a pharmaceutically acceptable salt thereof.

### Claim 23

(canceled)

### Claim 24

A method of treating a patient that is in need of anti-platelet therapy, comprising administering a therapeutically effective amount of a compound of formula I:
where:
X and Y are —CH—, or X is —CH— and Y is —N—, or X is —N— and Y is —CH—;
R1 is selected from —C1-6alkyl optionally substituted with 1 to 5 groups selected from halo, —NHC(O)CH3, and —C(O)NHCH3; —C3-6cycloalkyl; —C1-2alkylene-OR; —C1-2alkylene-COOR; —C0-3alkylene-phenyl optionally substituted with —NHC(O)CH3 or —C(O)NHCH3; and —C0-3alkylene-pyridyl; where R is selected from hydrogen and —C1-3alkyl;
R2 is selected from hydrogen, —C1-6alkyl, and —O—C1-6alkyl;
R3 is selected from hydrogen, halo, and cyano;
R4 is selected from halo; —C1-6alkyl optionally substituted with 1 to 5 fluoro atoms; —O—C1-6alkyl optionally substituted with 1 to 5 fluoro atoms; —C0-1alkylene-phenyl; —O—C0-3alkylene-phenyl; —SO2—C1-6alkyl; —C(O)NH2; and —NO2; and
n is 1 or 2;
or a pharmaceutically acceptable salt thereof.
